Why can’t I be having back issues 5 years from now!
First up – ISTO – they will be competing with Mesoblast.
NuQu, a cell-based therapy derived from ISTO’s platform technology for cartilage regeneration, is intended as an early intervention treatment for patients suffering from low back pain by potentially repairing, regenerating and restoring function to the disc. In preclinical studies, the juvenile chondrocytes used in the NuQu program have shown to have far greater regenerative potential than adult cartilage cells in both in vitro and in vivo environments.
Next up is Cornell Univeristy engineering new invertebral discs. Dr. Hartl is about 5 years away from a clinical application and this sounds VERY promising. I’m guessing they will also have to sever the ALL in the installation mind you. An ounce of prevention…
I’m going to inquire about the NUQU clinical trial.